Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter [Yahoo! Finance]
Aytu BioPharma, Inc. (AYTU)
NASDAQ:AMEX Investor Relations:
aytubio.com/investors/stock-information
Company Research
Source: Yahoo! Finance
Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 million Q2 2024 ADHD Portfolio net revenue up 49% compared to Q2 2023 $19.5 million cash balance at December 31, 2023 Company to host conference call and webcast today, February 14, 2024 at 4:30 p.m. Eastern time DENVER, CO / ACCESSWIRE / February 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter. Q2 2024 Highlights Consolidated net revenue was $22.9 million, compared to $26.3 million in the prior year period. The decrease is primarily due to the planned wind down of the Company's Consumer Health Segment. ADHD Portfolio (Adzenys XR-ODT ® and Cotempla XR-ODT ® ) net revenue increased 49% to $16.6 million, compared to $11.1 million in the prior year period. Net revenue from the Company's Rx
Show less
Read more
Impact Snapshot
Event Time:
AYTU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AYTU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AYTU alerts
High impacting Aytu BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AYTU
News
- Global Male Infertility Market Size To Worth USD 5.34 Billion By 2033 | CAGR of 3.49% [Yahoo! Finance]Yahoo! Finance
- Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024 [Yahoo! Finance]Yahoo! Finance
- Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024Accesswire
- Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second QuarterAccesswire
AYTU
Sec Filings
- 4/2/24 - Form 4
- 2/14/24 - Form 8-K
- 2/14/24 - Form 10-Q
- AYTU's page on the SEC website